A Study of Once-Daily NNC0090-2746 in Participants With Type 2 Diabetes Inadequately Controlled With Metformin
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 108 participants.
Also called NCT02205528
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 108 participants
- Sponsor
- Registry
-
NCT02205528
-
- Other papers using this trial's data
- The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT02205528. Randomized; double masking; primary purpose treatment. Start 2014-08-18 (actual); primary completion 2015-09-15 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of Once-Daily NNC0090-2746 in Participants With Type 2 Diabetes Inadequately Controlled With Metformin
- Condition
- Diabetes
- Condition
- Diabetes Mellitus Type 2
- Intervention (Drug)
- Liraglutide
- Intervention (Drug)
- Metformin
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- NNC0090-2746
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct02205528- Content hash
2d38d2167d644acf8169ec36961e4be77ce71556b57a1e1a153245da7ac8fad4